《半日總結》恆指跌163點 舜宇、瑞聲及科技股受壓
恆指反覆跌163點穿兩萬九。美國金融市場昨日(5日)休市。在科網平臺監管風險下，本港科技股昨日受壓，拖累恆指向下。恆指今早低開6點後顯着受壓穿兩萬九，最多跌238點，低見27,904點，續創5月14日以來新低，其後反覆倒升，高見28,151，惟沽壓未止，恆指半日跌163點或0.6%，報27,980；國指跌41點或0.4%，報10,232。恆生科技指數跌104點或1.4%，報7,607。大市半日成交總額764.6億元。
騰訊(00700.HK)反覆靠穩升0.5%，報556.5元。小米(01810.HK)、阿裏巴巴(09988.HK)分別升0.2%、跌0.3%。阿裏健康(00241.HK)、平安好醫生(01833.HK)分別跌5.9%、4.9%，均爲表現最差恆生科技指數成份股。
友邦保險(01299.HK)、匯控(00005.HK)均升0.7%支撐大市。中移動(00941.HK)平收。中資金額股走勢偏好，中國平安(02318.HK)、工行(01398.HK)、建行(00939.HK)升0.7%-1.6%。
部份內房股銷售表現改善，股價逆市有支持。融創中國(01918.HK)上半年合同銷售3,207.6億人民幣，增64%，股價升1.4%。萬科企業(02202.HK)上半年合同銷售3,544億人民幣，增10.6%，股價升3.3%。花樣年(01777.HK)斥12.6億人幣收購上海綠閔物業管理全部股權，股價升1.2%
汽車股先高後低，比亞迪(01211.HK)上半年汽車產量增60%，銷量升55.5%，股價高開低走跌2.8%。東風集團(00489.HK)上半年產量增26.7%，多銷24.5%，股價跌4%。吉利(00175.HK)跌2%。
國家藥品監督管理局藥品審評中心(CDE)早前發佈新政，市場擔心訂單有影響，生物科技股受壓，石藥(01093.HK)、藥明生物(02269.HK)分別挫5.7%、12.6%。昭衍新藥(06127.HK)、泰格醫藥(03347.HK)、康方生物(09926.HK)、藥明康德(02359.HK)、信達生物(01801.HK)分別挫10.8%、10.6%、8.7%、8.6%、4.8%。
遭東股減持的錦欣生殖(01951)插9.7%。據報主要股東擬近指引下限減持。復銳醫療(01696.HK)預計上半年溢利增加逾190%，股價揚8%。廣匯寶信(01293.HK)料上半年純利按年升最少3倍，早市股價漲15.5%。(ta/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
